The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...